Pliant Therapeutics, Inc. (PLRX)
| Market Cap | 65.02M -28.4% |
| Revenue (ttm) | n/a |
| Net Income | -92.29M |
| EPS | -1.50 |
| Shares Out | 61.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 379,553 |
| Open | 1.100 |
| Previous Close | 1.080 |
| Day's Range | 1.050 - 1.100 |
| 52-Week Range | 1.020 - 1.950 |
| Beta | 1.28 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 5, 2026 |
About PLRX
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company’s lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of αvß8 and αvß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics,... [Read more]
Financial Performance
Financial StatementsNews
Pliant Therapeutics appoints David Raben as Chief Medical Officer
Pliant Therapeutics (PLRX) announced the appointment of David Raben, M.D., as Chief Medical Officer. Raben brings more than 30 years of experience in academic translational research, clinical care, an...
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
Leader in targeted immuno-oncology drug development brings three decades of academic and biopharmaceutical oncology expertise
Pliant Therapeutics receives Fast Track designation from FDA for PLN-101095
Pliant Therapeutics (PLRX) announced the receipt of Fast Track designation from the FDA for PLN-101095, an oral, small molecule, dual selective inhibitor in combination with pembrolizumab for the pote...
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration...
Pliant Therapeutics reports Q2 EPS (36c), consensus (34c)
“In the second quarter, we continued to execute across the portfolio, led by strong enrollment in FORTIFY,” said Bernard Coulie, President and Chief Executive Officer of Pliant. “With the appointments...
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
FORTIFY, a Phase 1b indication expansion trial of PLN-101095, experiencing strong enrollment Appointed seasoned oncology drug development leaders Flavia Borellini, Ph.D. and Robert Iannone, M.D.
Pliant Therapeutics Quarterly report: Q2 2026
Pliant Therapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.
Pliant Therapeutics Earnings release: Q2 2026
Pliant Therapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D.
Appointments bring global oncology drug development experience and deepen Board's operational and regulatory expertise
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Ther...
Pliant Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
The company presented promising early clinical data for its integrin-blocking oncology program, with durable responses and a robust biomarker strategy. Preclinical siRNA delivery efforts are advancing, with muscle-targeting studies in primates and data expected this year. Key clinical and platform milestones are anticipated in 2026 and 2027.
Pliant Therapeutics reports Q1 EPS (32c), consensus (36c)
“In the first quarter, our team showcased its clinical development capabilities, initiating FORTIFY, the Phase 1b trial of PLN-101095, ahead of schedule and dosing the first patient in April,” said…
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095 Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095 showing deepening of confi...
Pliant Therapeutics Earnings release: Q1 2026
Pliant Therapeutics released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Pliant Therapeutics Quarterly report: Q1 2026
Pliant Therapeutics has published its Q1 2026 quarterly earnings report on May 11, 2026.
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-base...
Pliant Therapeutics doses first participant in FORTIFY expansion trial
Pliant Therapeutics (PLRX) announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical trial of PLN-101095 in combination with pembrolizumab, in pati...
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics (Nasdaq: PLRX) today announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication exp...
Pliant Therapeutics Proxy statement: Proxy filing
Pliant Therapeutics filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Pliant Therapeutics Proxy statement: Proxy filing
Pliant Therapeutics filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Pliant announces presentation of updated data from Phase 1 trial of PLN-101095
Pliant Therapeutics (PLRX) announced the presentation of updated data from its Phase 1 trial of PLN-101095, in combination with pembrolizumab, in patients with immune checkpoint inhibitor-refractory a...
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months
Pliant Therapeutics files $300M mixed securities shelf
18:00 EDT Pliant Therapeutics (PLRX) files $300M mixed securities shelf
Pliant Therapeutics Registration statement: Registration filing
Pliant Therapeutics filed a registration statement on March 30, 2026, providing details about a securities offering with the SEC.
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-ba...